Skip to main content
Premium Trial:

Request an Annual Quote

DCN, Asahi Kasei Fibers Partner on Nanobeads for Assay Development

NEW YORK (GenomeWeb News) – DCN Diagnostics today announced a deal with Asahi Kasei Fibers for the distribution of Asahi's cellulose nanobead product in North America.

Additionally, DCN, formerly called Diagnostic Consulting Network, will be the preferred provider of original equipment manufacturing services to users of Asahi's product, called NanoAct, worldwide, except in Japan, where Asahi is based.

NanoAct products comprise a range of high-intensity colored beads, which can be multiplexed. They generate higher sensitivity, lower coefficients of variation, and better stability than other visual labels such as colloidal gold, DCN said.

"We believe that NanoAct will allow for the development of higher performing lateral flow tests," CDN President Brendan O'Farrell said in a statement. "Coupled with DCN's assay development, training and customer support capabilities, we believe that this product line will allow for product performance that can have significant impact in many markets."

Financial and other terms were not disclosed.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.